
|Articles|May 1, 2003
Combination agents target early, late stages of allergy
Author(s)Nancy Groves, Mark Silverberg, MD
Ophthalmic drops that combine immediate antihistamine relief with prophylactic care in the form of mast cell inhibition and eosinophil blockage are the mainstay of therapy for allergic conjunctivitis.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Ophthalmology pipeline watch: Key trial results and PDUFA dates for Q1 2026
2
PRIMA retinal implant restores vision in patients with advanced GA
3
Ocugen releases positive preliminary 12-month data from phase 2 ArMaDa trial
4
Ocugen publishes phase 1 GARDian1 gene therapy data for Stargardt disease
5














































